AEZS | AEterna Zentaris Inc. (USA)
Aeterna Zentaris is a specialty biopharmaceutical company focused on developing and commercializing, principally through out-licensing, macimorelin, an oral growth hormone secretagogue receptor agonist indicated for the diagnosis of Adult Growth Hormone Deficiency (AGHD), a rare endocrine disorder. Aeterna Zentaris owns the worldwide rights to macimorelin and has significant patent protection left. The Companyâs U.S. composition of matter patent expires in 2022 and our U.S. utility patent runs through 2027. Macimorelin was invented and first synthesized by the research group of Professor Martinez at the University of Montpellier, Centre National de la Recherche Scientitifique (CNRS). This transpired from a long-lasting research collaboration with Aeterna Zentaris. Aeterna Zentaris later in-licensed macimorelin as a development candidate from the CNRS and proceeded with the pre-clinical and clinical development of the compound.
About the Company
Ãterna Zentaris Inc. is a Quebec, Canada-based biopharmaceutical drug development company focused in oncology and endocrine therapy, currently investigating treatments for various unmet medical needs.
If you want to help pay for server cost or for improving this tool. You can send it via Paypal.
Buy on Amazon
Technical analysis is a collection of techniques designed to help you make trading decisions in securities markets. Technical Analysis For Dummies helps you take a hard-headed look at what securities prices are actually doing rather than what economists or analysts say they should be doing, giving you the know-how to use that data to decide whether to buy or sell individual securities.
A simple, straightforward guide to the fundamentals of technical analysis